Patients with Marfan syndrome usually suffer acute type A aortic dissection in the fourth or fifth decade of life. Emergent replacement of their ascending and aortic arch segments does not eliminate the risk of later aortic complications affecting their life expectancy because in fact their entire aorta is structurally abnormal. Surgery for type A dissection in Marfan syndrome patients has low in-hospital mortality risk. Nevertheless, survivors carry a high risk of aortic complications in the untreated segments and frequent pathologies at the graft--native aorta junction. The extent of the initial surgical aortic repair is associated with the need for reoperations during the patient's follow-up. Leaving aortic root tissue behind leads to high complication rates, and up to 40% of patients require a second sternotomy for aortic root replacement later in life. Therefore, aortic root replacement or repair should be undertaken in all patients with Marfan syndrome with type A dissection. Total aortic arch replacement reduces the number of aortic arch reinterventions. However, if secondary aortic arch surgery is performed electively, the risk it carries is acceptable. The decision to extend initial aortic repair is considered in all patients on an individual basis. Patients with Marfan syndrome type A dissection seem to benefit from extended aortic root repair, including root or valve-sparing root replacement, whereas total aortic arch replacement is unnecessary unless there are primary tears in the arch itself. See p 1381.
Risk for Myocardial Infarction and Stroke After Community-Acquired Bacteremia: A 20-Year PopulationBased Cohort Study
Recent research suggests that patients who acquire an infection may have a transient increased risk of cardiovascular events. Acute myocardial infarction (AMI) and acute ischemic stroke (AIS) are common, and any role of acute infections in triggering them is of major clinical interest. We investigated short-and longer-term risks of AMI and AIS among >4000 patients with microbiologically verified community-acquired bacteremia. Within the first 30 days, 3.6% of bacteremia patients experienced an AMI or AIS. Their adjusted risk was >2-fold higher than in other acutely hospitalized patients, and 20-fold increased in comparison with the background population. A modestly increased risk in particular for AIS persisted up to 6 months after bacteremia. High risks of AMI and AIS were seen in patients with endocarditis, Staphylococcus aureus bacteremia, high levels of inflammatory markers, or intensive care unit stay. A high absolute risk for AMI and AIS was also found among those with previous cardiovascular disease, which underlines current vaccine recommendations. Further studies are needed to clarify the mechanisms, including metabolic supply/demand mismatch and embolic events that may increase the risk for cardiovascular events following severe infection. Such knowledge may improve prevention, early diagnosis, and targeted management of AMI and AIS in patients with ongoing bacteremia. As the burden of hospitalization with bacteremia continues to grow, clinicians should be aware of the possible link between bacteremia and thromboembolic events. See p 1387.
Double-Stranded RNA-Dependent Protein Kinase Deficiency Protects the Heart From Systolic OverloadInduced Congestive Heart Failure
Congestive heart failure (CHF) is a major cardiovascular disease of epidemic proportions that has increased in prevalence in the past few decades. Identification of underlying factors that worsen heart function in CHF is necessary for the development of effective therapeutics. Double-stranded RNA-dependent protein kinase (PKR) represses protein synthesis under stress conditions by phosphorylating eukaryotic initiation factor 2α. PKR inhibition has been recognized as an attractive therapeutic target in clinical conditions such as cancer, inflammation, and Alzheimer disease, and specific pharmacological inhibitors of PKR are under development for clinical use. Our findings identify PKR as a maladaptive factor in the heart that is upregulated in hemodynamic overload and promotes the development of CHF. PKR expression and activation were increased in human and mouse failing hearts, whereas genetic disruption of PKR protected against pressure overload-induced CHF. Mechanistically, PKR disruption blunted transverse aortic constriction-induced myocardial inflammatory cytokine expression and protected against cardiomyocyte apoptosis, indicating that PKR promotes the development of CHF by amplifying inflammatory pathways and sensitizing cardiomyocytes to apoptotic stimuli. Our study provides the first direct evidence that PKR inhibition may be an attractive new therapeutic target in treating CHF. See p 1397.
National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation
This article reports results from a unique data source, Quest Diagnostics, which provides laboratory testing services to approximately half of the physician practices in the United States. We identified 138 319 individuals referred by 37 939 physicians, providing a total of 2 683 674 international normalized ratio results. Unique to Quest Diagnostics, all international normalized ratio assays are standardized across US laboratories, essentially eliminating any variability in international normalized ratio measurement introduced by differences in methodology, reagents, and instruments. The mean age of the population was 74 years; 55% were ≥75 years of age. The overall mean time in the therapeutic range was 53.7% (48% for patients with <6 months of testing and 58% for patients with ≥6 months of testing). Physician referral panel size was positively associated with time in the therapeutic range; nearly 95% of the ordering physicians referred <10 patients. Younger age, female sex, and lower income were also found to be independently associated with poorer anticoagulant control. We believe these results provide the most comprehensive Volume 129 ◼ Number 13 ◼ April 1, 2014 By demonstrating that postprocedural aortic regurgitation (AR)≥grade 2 was observed by echocardiography in 15.8% of successful transcatheter aortic valve replacements and was the strongest independent predictor of 1-year mortality, the present study provides important information on the clinical significance of postprocedural AR after an otherwise successful transcatheter aortic valve replacement procedure. These results extend previous findings regarding the significance of AR as observed by angiography or by echocardiography with a balloon-expandable device in the Placement of Aortic Transcatheter Valve (PARTNER) Trial. They further suggest that postprocedural AR≥grade 2, but not postprocedural AR=grade 1 (mild), is a powerful independent predictor of mortality, whereas the occurrence of such postprocedural AR≥grade 2 can be specifically deleterious in some populations (renal failure, low transaortic gradient, patients treated through a nonfemoral approach, etc), whereas others have a better tolerance of AR (patients with AR before the procedure). Our study further demonstrates that the incidence of postprocedural AR≥grade 2 is higher with self-expandable than balloon-expandable devices (21.5% versus 13.0%, P=0.0001). This was observed on univariable analysis and confirmed by extensive multivariable analysis, where the use of the self-expandable device was one of the most powerful independent predictors of the occurrence of postprocedural AR≥grade 2. The lower rate of postprocedural ARs associated with nonfemoral delivery, in particular with a self-expandable device, may suggest that improving delivery catheter technology and the precision of delivery during femoral procedures could lead to a significant reduction in the occurrence of such ARs. The difference in predictors of postprocedural ARs, in particular, the role of aortic annulus and prosthesis diameters, suggests specific pathways of improvement for the balloonexpandable and the self-expandable device. See p 1415.
Endothelial Cell-Specific Liver Kinase B1 Deletion Causes Endothelial Dysfunction and Hypertension in Mice In Vivo
Endothelial dysfunction is associated with many cardiovascular diseases. Liver kinase B1(LKB1), a serine/threonine protein kinase for the AMP kinase family, is a known tumor suppressor gene in Peutz-Jeghers syndrome. However, its contribution to vascular function and blood pressure homeostasis remains unknown. In the present study, we have shown that LKB1 is critically involved in vascular function. Genetic endothelium-specific deletion of LKB1 in mice resulted in impaired endothelial nitric oxide synthase-dependent vasodilation, which was associated with elevated blood pressure and cardiac hypertrophy. Mechanistically, this phenotype was attributed to the excessive translocation of human antigen R, thus increasing caveolin-1 expression, which decreased endothelial nitric oxide synthase activity. Furthermore, administration of constitutively active AMP kinase improved endothelial function and decreased blood pressure in endothelium-specific LKB1 knockout mice. These observations unveil new facets of LKB1 that may link energy metabolism with endothelial function and vascular diseases. Our novel findings support the notion that LKB1 is a potential therapeutic target for combating vascular dysfunction associated with vascular diseases such as hypertension. See p 1428.
